Skip to main content
As published for the week of Monday, October 24, 2016

  • Cover Story: Lilly's history lesson

    Commercial execution key to growth for incoming Lilly CEO Ricks

    By Erin McCallister, Senior Editor

    Eli Lilly and Co. President and CEO-in-waiting David Ricks will inherit a well-stocked pipeline, seven drugs less than three years old and a much-improved growth trajectory. To maintain momentum, he'll have to execute on the recent launches in crowded markets to make up for three of Lilly's top-selling drugs going off patent in the next two years.

    Ricks told BioCentury he plans to draw from the playbook used to build blockbuster franchises for erectile dysfunction drug Cialis tadalafil, which was third to market, and Forteo teriparatide, an injectable agent launched into an osteoporosis market dominated by oral bisphosphonates.

    Full Article

Money Raised in 2016

Last week, the biotech industry raised $1,246 million, bringing to $72.5 billion the total raised year-to-date. In 2015, a total of $108.9 billion was raised, including $54.8 billion in debt, $29.6 billion in follow-ons, $3.8 billion in PIPEs and other equity, $8.1 billion in IPOs, and $12.7 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results